Using CALR test results to track certain blood cancers
Part of Blood & lymphatic clinical trials.
This study looks at how much of a specific gene change (CALR) you have, and whether it helps doctors diagnose and follow people with certain blood cancers over time. It mainly involves using samples and medical data rather than testing a new drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are covered by France’s national social security system
- You were diagnosed between 2006 and 2020 with a CALR-mutated myeloproliferative neoplasm (a specific type of blood cancer)
- A sample from before diagnosis or before starting chemotherapy (cytoreductive treatment) is available
- You agree to take part in the study and are included (or will be included) in the French national clinical-biological database (FIM)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune cells (monocytes) in people with certain blood cancers. Researchers want to understand how these cells behave and change over time. You can join if you are newly diagnosed and haven't started treatment yet.
This study looks at cells from people with a specific gene change called CALR, found in some blood cancers (myeloproliferative neoplasms). It aims to better understand how the disease works. No new treatments are being tested, but you may help researchers learn more about your condition.
This Phase 1 study tests a vaccine made from a CALR mutation (a specific genetic change) to help the immune system recognize and fight your blood cancer. It is mainly focused on early safety and to see if the vaccine can trigger an immune response in people with CALR-mutated myeloproliferative neoplasms.
This study tests a new drug called INCA033989 for people with a high-risk form of essential thrombocythemia (a blood disorder causing too many platelets) who have a specific genetic change called mutCALR. The trial compares this new drug to the best currently available treatments.
This study is a “registry,” meaning it collects information about adults with specific types of myeloproliferative neoplasms (MPNs). It helps researchers better understand these diseases and may improve future care.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.